EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Sequential use of fibroblast activation protein targeted radiotherapy and CAR-T therapy enhances the anti-tumor response in pancreatic ductal adenocarcinoma

Wenhao Niu, Binchen Wang, Yirui Zhang, Jing Cao, Jiali Li, Kui Xu, Yibing Lv, Junyi Xiao, Mingxuan Li, Tingting Wang, Yong He, Ping Lei

Cancer Immunology, Immunotherapy · 19.11.2026

DOI: 10.1007/s00262-026-04642-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 19.11.2026. Verfasst von Wenhao Niu und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Niu, W., Wang, B., Zhang, Y., Cao, J., Li, J., Xu, K., Lv, Y., Xiao, J., Li, M., Wang, T., He, Y., & Lei, P. (2026). Sequential use of fibroblast activation protein targeted radiotherapy and CAR-T therapy enhances the anti-tumor response in pancreatic ductal adenocarcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04642-2

Vancouver

Niu W, Wang B, Zhang Y, Cao J, Li J, Xu K, et al. Sequential use of fibroblast activation protein targeted radiotherapy and CAR-T therapy enhances the anti-tumor response in pancreatic ductal adenocarcinoma. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04642-2

BibTeX
@article{Niu2026,
  author = {Niu, Wenhao and Wang, Binchen and Zhang, Yirui and Cao, Jing and Li, Jiali and Xu, Kui and Lv, Yibing and Xiao, Junyi and Li, Mingxuan and Wang, Tingting and He, Yong and Lei, Ping},
  title = {Sequential use of fibroblast activation protein targeted radiotherapy and CAR-T therapy enhances the anti-tumor response in pancreatic ductal adenocarcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04642-2}
}
Kostenlos starten →